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ABSTRACT
COMPARISON OF CPU AND PARABRICKS GPU ENABLED BIOINFORMATICS SOFTWARE
FOR HIGH THROUGHPUT CLINICAL GENOMIC APPLICATIONS

Stefano Rosati, B.A.
Marquette University, 2020
In recent years, high performance computing (HPC) has begun to revolutionize
the architecture of software and servers to meet the ever-increasing demand for speed
& efficiency. One of the ways this change is manifesting is the adoption of graphics
processor units (GPUs). Used correctly, GPUS can increase throughput and decrease
compute time for certain computational problems. Bioinformatics, an HPC dependent
discipline, is no exception. As bioinformatics continues advance clinical care by
sequencing patient’s DNA and RNA for diagnosis of diseases, there is an ever-increasing
demand for faster data processing to improve clinical sequencing turnaround time.
Parabricks, a GPU enabled bioinformatics software is one of the leaders in ‘lifting
over’ common CPU bioinformatics tools to GPU architectures. In the present study,
bioinformatics pipelines built with Parabricks GPU enabled software are compared with
standard CPU bioinformatics software. Pipeline results and run performance
comparisons are performed to show the impact this technology change can have for a
medium sized computational cluster.
The present study finds that Parabricks’ GPU workflows show a massive increase
in overall efficiency by cutting overall run time by roughly 21x, cutting overall
computational hours needed by 650x. Parabricks GPU workflows show a 99.5% variant
call concordance rate when compared to clinically validated CPU workflows.
Substitution of Parabricks GPU alignment into a clinically validated CPU based pipeline
reduces the number of compute hours from 836 hours to 727 hours and returns the
same results, showing CPU and GPU’s can be used together to reduce pipeline
turnaround time & compute resource burden. Overall, integration of GPUs into
bioinformatic pipelines leads to massive reduction of turnaround time, reduction of
computation times, and increased throughput, with little to no sacrifice in overall output
quality. The findings of this study show GPU based bioinformatic workflows, like
Parabricks, could greatly improve whole genome sequencing accessibility for clinical use
by reduction of testing turnaround time.
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INTRODUCTION
Background
The fields of bioinformatics and clinical genomics have grown rapidly with the
rise of next generation sequencing and the subsequent increase in publicly available
data and decrease in the cost to generate genomic data. Despite the growth of the
clinical genomics, clinical sequencing still faces challenges in becoming a routine
diagnostic test, causing it to remain a last-ditch effort to end a diagnostic odyssey. Of
the major challenges facing whole genome sequencing (WGS), the high cost and long
turnaround time (TAT), the time from test order through results reporting, remain the
largest hurdles to making whole genome sequencing (WGS) a staple of diagnostic
testing (Manolio, 2017). While advances in sequencing technology and testing
availability have improved clinical WGS TAT, bioinformatic computation and variant
analysis remain a challenge due to the volume of data and amount of hands on time
required by analysts (Miller, 2015). Within this study, a new graphics processor unit
(GPUs) based bioinformatics toolset called Parabricks is assessed against standard
bioinformatics pipelines using central processing units (CPUs), showing drastic reduction
of TAT with no sacrifice in clinical efficacy.
Clinical Genomics
Since the start of the Human Genome Project, integration of computer science
into genetic sequencing has played a key role in the growth of genomics for research
and clinical applications (Lander, 2001), (Hood, 2003). As computer science and data
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analysis have become more intertwined, the cost of sequencing has reduced drastically.
Estimates published in 2018 show clinical whole exome sequencing (WES) ranges from
$555 to $5,169 and clinical whole genome sequencing (WGS) from $1,906 to $24,810
(Schwarze, 2018). While current WES and WGS costs are still prohibitive for most
patients, the current price is a drastic reduction from the 2.7 billion dollar price tag of
the first human genome in 2003 (National Institute of Health, n.d.). The decrease in
sequencing cost is driven by technological innovations allowing for high throughput
sequencing of many samples in parallel called Next Generation Sequencing (NGS)
(Schwarze, 2018). As the cost of sequencing continues decreases, NGS has continually
showed its ability to transforming the diagnostic methods for finding causes of both rare
& common mendelian diseases, as well as providing accurate diagnosis and targeted
treatment of cancer (Cirulli, 2010) (Willig, 2015).
Despite the price decrease of WES and WGS testing in recent years, the world of
clinical genomics still faces challenges. The largest challenges remain turnaround time
(TAT), variant interpretation and data management (Rossen, 2018) (Meienberg, 2016).
A single patient’s WGS data can result in hundreds of gigabytes of data and can take
thousands of hours of server time (Muir, 2016). In recent years, the growth of cloud
computing and storage has decreased the cost of maintaining servers and have made it
easier to scale up workflows, but has not done much to increase the use of WGS over
using smaller exome and genome panels (Muir, 2016). At present, it remains much more
effective for clinicians to order smaller gene panels and WES than WGS due to the lower
cost and faster TAT (Muir, 2016). Smaller gene panels are attractive to clinicians and
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patients due to their lower cost, as they require less sequencing, less computation and
less hands-on analytical time.
Despite the drawbacks of high data volume, long compute time, and costly
hands variant curation requirements, there is little disagreement that WGS is a highly
effective method for clinical diagnostics. Many clinicians argue that WGS should be a
front line defense for neonatal crises and should be utilized in the management of acute
medical care (Miller, 2015) (Saunders, 2012) (Manolio, 2017). WGS has been shown to
help in these scenarios by assisting in diagnosing rare and new diseases, diagnosing
cases with atypical presentation and can help in cases where standard treatments are
ineffective (Miller, 2015). WGS findings additionally assist clinicians in managing and
treating diseases by giving insights into a disease’s etiology, offering clinicians insights
into treatment as opposed to long term management of symptoms (Clark, 2019). WGS
sequencing also has the ability to show clinicians when irremediable damage is done to
the genome, allowing them to begin palliative care knowing they have done all they can
for their patients without prolonging suffering (Willig, 2015).
WGS additionally provides methodological benefit by superior data to target
sequencing methodologies such sequencing by exome capture or PCR amplification.
WGS’ indiscriminate method of genome surveillance and variant detection can lead to
detection of previously unknown pathogenic disease origins (Lionel, 2018). Whole
genome sequencing also has better resolution for calling copy number variants (CNVs),
large genomic deletions or insertions, by increasing the probability of sequencing over
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breakpoints and by giving better resolution of large genomic events (Lionel, 2018). By
contrast, exome and targeted panels have difficulty detecting CNVs, due to the finite
targets, and limited resolution (Zhao, 2013). Perhaps counterintuitively, a negative
result from a WGS test is more significant result than a negative targeted panel. This
means that a negative result from WGS testing is less likely to leave clinicians and
patients wondering if they need to order a more comprehensive or advanced test.
Another scenario in which WGS sequencing has utility is neonatal crisis, where
any of an estimated 500-1000 different genes can drive newborns to rapidly deteriorate
(Kingsmore, 2012). Neonatal crises account for around 20% of newborn deaths in the
US and up to 18% of newborn hospitalizations (Kingsmore, 2012). Many these
syndromes and metabolic conditions are reversible and preventable if detected early
and treatment is administered within a reasonable amount of time. Two such examples
of preventable & manageable diseases include phenylketonuria (PKU) and congenital
hypothyroidism which effect 1 in 10,000 and 1 in 2,000 newborns respectively
(Kingsmore, 2012). While the cost of WGS testing might seem cost prohibitive for
routine use in diagnoses of rare diseases, the cost of testing is much more reasonable
when compared to a daily price tag of $3,500+ in the Neonatal Intensive Care Unit
(NICU) (Muraskas & Parsi, 2008). However, current WGS turnaround times of 1-2
months remain woefully insufficient to make an impact in many cases (Thiffault, 2019).
The speed of WGS sequencing and analysis continues to prevent the power of the
method from being brought into everyday clinical use.
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Computational Challenges
Central processing units (CPUs) are the standard calculator that perform
computations within a computer. Throughout the rise of computers, the driving force
increasing computer performance and software speed was the advancement of CPU
speed. This concept has termed “Moore’s Law”, named after the author of the
landmark 1965 paper, posits, “The complexity for minimum component costs has
increased at a rate of roughly a factor of two per year” (Moore, 1998). This phrase was
come to be understood that computational power of standard CPUs would double every
12-18 months and has been remarkably accurate over the last half century.
More recently, Moore’s law has run out of runway. While transistors per chip
continues to double every 12-18 months, speeds of processors have reached a plateau
(Waldrop 2016) (Figure 1). The driver of this plateau is that CPU hardware is
approaching fundamental physical limitations, in which speeds cannot improve the
speed without employing super cooling or involving massive power consumption
(Markov, 2014). The consequences of this phenomenon are far reaching. Previously, if a
developer wrote a piece of software, all they would need to do to make it go faster is
wait for a faster generation of processers to come out. Now, to achieve greater
performance developers need to get more creative in their coding or must look to new
computer architectures to increase efficiency.

6
Figure 1: A plot showing the relationship between clock speed and transistors per chip over the last 50
years. (Waldrop, 2016)

One such architectural solution is the multi-core processor, in which multiple
processors work in sync to accomplish tasks. Provided the software used can operate
with multiple CPUs, this improvement allows for large tasks to be spread across many
CPUs to accomplish the task sooner. While multicore processing can increase the
number of computations that can be done in a given amount of time, it has some
notable drawbacks. One of the most important predictors of a computational task’s
speed increase is parallelizability, termed “f”.
Each unique combination of computational task, operating system and hardware
combine to create a unique f value. In general, each additional CPU assigned to a task
increases the speed but depending on the parallelizability of the task (f), there is a
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diminishing return in overall CPU efficiency (Figure 2). This diminishing return on CPU
resource investment is known as Ahmdal’s law (Sun, 2010). This means that efficiency
and fold speed up of adding more CPUs to speed up a computation is gated by f. As f
decreases, so does the return on investment for each CPU added to a computation. As
bioinformaticians and software engineers look to increase the speed of WGS pipelines,
they are forced to re-design how their code functions, break tasks into many parts, or
look to other computational architecture in order to increase the parallelizability.

Figure 2: A representation of the relationship between the parallelizability (f) of a
computational job, the number of CPU cores assigned to it, and the fold speedup of the
job’s completion (Sun, 2010)

Graphics processor units (GPUs) represent another of the solution to HPC
throughput. GPUs initial purpose were specifically for high resolution screens- where
computations must be performed to render millions of pixels hundreds of times per
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second. GPUs are rapidly being adopted into HPC workflows as they can outperform
CPUs for tasks that require many simple computations at once (Nickolls, 2010). By using
code specifically designed for GPUs, GPU architectures can work in synergy with CPUs to
massively speed up computational jobs. While GPUs can represent a large performance
upgrade, the drawback is increased difficulty in code design and great difficulty involved
in troubleshooting.
Bioinformatics as a discipline is extremely familiar with high complexity HPC
problems. For example, in alignment of a single sequencing ‘read’ consisting of a string
of 200-300 As, Ts, Cs, and Gs to the human genome, must compute the ‘optimal’
placement of the read into to a genome 3.2 billion bases in length. This matrix
multiplication must be performed one or more times for each sequencing read in a
genome. A standard clinical WGS sequencing can produce upwards of 500 million reads.
Meaning this N x M computation could be performed 500 million times to create a
single base alignment map file (BAM file). Even divided across many different CPU
processors, this computation can take hours or days to complete. Fortunately, genome
alignments matrix multiplication is what many in the computer science industry call a
“ridiculously parallel” problem, meaning no single computation is dependent on any
other. This makes alignment and many bioinformatic tasks perfectly suited to GPU
workflows. Until now, one of the greatest drawbacks to implementing GPU workflows is
the difficulty of troubleshooting errors when they arise, and the difficulty of
implementing GPU workflows into pipelines.
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GATK & Parabricks Bioinformatics Tool Suites
The Genome Analysis Tool Kit (GATK) is a suite of open sourced highly versatile
Java based bioinformatics tools from the Broad Institute is an (Van der Auwera, 2013).
GATK has tools ranging from raw read trimming to de novo genome assembly to
alignment of raw reads to reference genomes to somatic & germline variant calling
(Rimmer, 2014) (Van der Auwera, 2013). GATK’s wide user base and vast
documentation makes is a favorite of bioinformaticians. While extremely reliable,
GATK’s major drawback is currently that it is CPU based and its distributed SPARK
architecture has been for development use only since 2017.
Parabricks, now a product of NVIDIA, is a commercially available tool which
converts GATK based functions and algorithms their native CPU architecture to a GPU
architecture (Figure 3). Parabricks functions by keeping the underlying GATK tools the
same, but adapts the most critical & parallelizable algorithms over to GPU enabled
CUDA code (NVIDIA (Parabricks), 2020) (NVIDIA (CUDA), 2020). The Parabricks software

Figure 3: Currently available Bioinformatics tools within the Parabricks software suite.
(Parabricks, 2020)
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is specifically written for the NVIDIA DGX-1, a single unit that contains 8 separate GPUs.
Parabricks boasts that their software can cut GATK pipeline turnaround times (TAT) by
40-60 times (NVIDIA (Parabricks), 2020). If true, this reduction in TAT poses a
breakthrough in bioinformatics that has the ability to increase WGS throughput, cut
WGS TAT and have a positive impact for patients and clinicians alike.
Study Objective
The goal of this study is to test Parabricks GPU enabled bioinformatic workflows
and tools against clinically validated CPU bioinformatic workflows for efficacy of clinical
whole genome sequencing (WGS). Evaluations for each pipeline include overall
bioinformatic workflow turnaround time (TAT), genome alignment TAT and
performance assessment of variant calling on National Institute of Standards and
Technology (NIST) Gold Standard Genome in a Bottle sample NA12878. Parabricks
claims to reduce pipeline TAT by 40x to 60x over standard GATK pipelines with no
sacrifice in output quality. If their claims are true, Parabricks has ability to revolutionize
whole genome sequencing by reducing WGS TAT and increasing the clinical utility of
WGS testing for labs, clinicians, and most importantly patients.
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METHODS & MATERIALS
Sequencing Data
The comparisons performed within this document were performed on 3 deidentified human samples from DNA. WGS-High Coverage (WGS-HC), a deeply
sequenced genome sample with about 150x coverage of the genome, WGS-Normal
Coverage (WGS-NC), 55x sequencing depth, and the Genome in a Bottle (GIAB) NA12878
national reference sample purified from cell line (National Institute of Standards and
Technology, 2020). All samples had library preparation with Illumina’s TruSeq Nano
Whole Genome preparation per manufacturer specifications (Illumina, 2020). All
samples were sequenced bi-directionally with 2x150 reads on the same Illumina
NovaSeq using an SP flowcell. Raw read data was prepared using of BCL2Fastq2 v2.20
and was stored in fastq.gz format (Illumina, 2019).
Pipelines Tested
3 Separate pipelines were tested within this study all aligning to Genome
Reference Consortium Human Build 37 (GRCh37) genome (Church, 2011). The three
pipelines tested in this study were: 1) ‘Clinically Validated CPU’ based, Whole Genome
Sequencing (WGS) pipeline based on GATK 2) ‘Parabricks Rapid’, a germline pipeline for
WGS built only on the Parabricks tool suite, 3) ‘Parabricks hybrid’ pipeline, a
combination of pipeline 1 and 2, in which the alignment is performed by Parabricks GPU
BWA alignment algorithm. All other tasks are performed by the standard CPU Pipeline.
The non-quality control pipeline features are summarized in Table 1.
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Table 1: Non-Quality control steps and software performing them in CPU, Hybrid and GPU
pipelines tested within this document.

Pipeline Step
Alignment
Mark Duplicates
Quality Score
Recalibration
Variant Caller
Genotype caller
GATK Variant
Normalization

CPU Pipeline

Hybrid Pipeline

GATK BWA-MEM

Parabricks BWAMEM Align
+ MarkDuplicates

Parabricks GPU
pipeline
Parabricks BWAMEM Align
+ MarkDuplicates

NA

NA

Picard Mark
Duplicates
GATK Base
Quality Score
Recalibration
(BQSR)
GATK haplotype
caller
GATK genotype
gVCF

GATK Base
Quality Score
Recalibration
(BQSR)
GATK haplotype
caller
GATK genotype
gVCF

BCFtools Norm

BCFtools Norm

Parabricks BQSR
Parabricks
Haplotype Caller
NA
NA

All GATK applications used within this study were performed on GATK version
4.1.2.0 (DROAZEN, 2019). Parabricks runs were performed on v2.4.6, using GATK
functions were lifted over from GATK v4.1.2.0.
Computation Environment
CPU based computations were performed on a 15 node HPC cluster consisting
340 Intel(R) Xeon(R) Gold 6154 3.00GHz CPUs, each node containing 6 TB of ddr3
memory. GPU computations are performed on a Nvidia DGX-One with 2-24 core 2x
Xeon Gold 8268 CPUs, and 8 NVIDIA Tesla P100 GPUs, and 512GB DDR4-2133 + 128GB
HBM2 memory. All systems used Linux Centos 7 as the operating system. All CPU and
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GPU compute jobs were managed by Torque v4.2.6 (Adaptive Computing, 2013) . GPU
computations were performed using CUDA v 10.1 (NVIDIA (CUDA), 2020).
Alignment Benchmarking
As genomic alignment tends to be the rate limiting step of most genomic
pipelines, an initial benchmarking of Parabricks Alignment + MarkDuplicates (BWA)
algorithm was performed using 2, 4 & 8 of the dedicated GPUs each in quadruplicate.
During the 2 and 4 GPU Parabricks alignment + mark duplicates assessments, all DGX
GPUs not under assessment were assigned alignment jobs to simulate uniform input /
output volume across the entire unit. Using the same sample input data, A GATK BWAMEM alignment + Mark Duplicates was performed in quadruplicate with 8 CPUs
dedicated using GATK best practices (GATK (Best Practices), 2020). Turnaround times of
2, 4 and 8 GPU Parabricks alignments were compared to CPU alignments.
Pipeline TAT Benchmarking
To test the turnaround time of the CPU, GPU and hybrid pipelines, each pipeline
was run from fastq files using sample WGS-HC (150x genome coverage), WGS-NC (55x
genome coverage), aligning to GRCh37. Each pipeline was run in duplicate and the
turnaround time was averaged. Turnaround time was measured from pipeline start to
completion.
A second analysis was performed on the same pipeline runs to compare the
Hybrid and CPU pipelines. The TAT of each step of the critical path, or longest path of
interdependent steps, was used to compare the difference Parabricks GPU alignment to
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GATK CPU alignment when all other steps remain the same. Job statistics were
obtained from the Torque scheduler logs.
Variant Calling Performance
The variant calling output for all three pipelines were assessed using NIST GIAB
sample NA12878 was used to assess variant calling performance of each pipeline. The
published NIST NA12878 ‘High Confidence’ variant call set was used to assess each
pipeline’s output VCF file (Zook J. M., 2019). The bed file for NA12878 high confidence
variant call files was bed intersected over all pipeline VCF files (Quinlan, 2010). The VCF
files for each pipeline, restricted to the high confidence regions, were then compared to
the NIST published high confidence variant calls from sample NA12878 using VCFtools’
vcf-compare (Danecek, 2011). The definitions of true positives, true negatives, false
positives and false negatives shown in Table 2 were used to assess performance.

Table 2: Definitions of performance metrics as used to assess GPU, CPU and hybrid
pipeline clinical efficacy.
Term

True Positive (TP)
True Negative (TN)

False Positive (FP)
False Negative (FN)
Sensitivity
Specificity

Definition

Matching reference and alternate allele between pipeline
output and published NA12878 high confidence call set
Site within the NA12878 high confidence region bedfile, but
with no variant calls in both pipeline VCF and NA12878 high
confidence variant call file
Site with variant call present in pipeline VCF output, but no
matching call in the NA12878 high confidence variant call
file
Site with no call in pipeline results VCF and a variant present
in NA12878 high confidence variant call
TP / (TP + FN)
TN / (FP + TN)
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Positive predictive
value (PPV)
Negative Predictive
value (NPV)

TP / (TP + FP)
TN / (FN + TN)
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RESULTS
CPU Alignment vs GPU Alignment
To assess the efficiency of alignment by Parabricks, the same fastq files were run
on the GATK based CPU pipeline, as well as the Parabricks pipeline, using 2, 4, and 8
dedicated GPUs to align and mark duplicate reads (Figure 4). All CPU alignments were
performed given 8 CPUs. All alignments on the CPU and GPU pipelines were performed
using the same GATK alignment parameters.

Figure 4: Alignment + Mark Duplicates comparison between Parabricks GPU alignment
using 2, 4 and 8 dedicated GPUs and GATK CPU alignment with 8 CPUs allocated.
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Comparing run times of the CPU and GPU architecture shows a stark difference
the overall time it takes for the genomic alignment and duplication marking to
complete. Running with only two dedicate GPUs, the alignment and mark duplicates
together runs twice as fast as the CPU duplicate marking alone. Comparing GPU
turnaround time of 150x depth WGS-High Coverage (WGS-HC) to the 55x depth WGSNormal Coverage (WGS-NC) shows that the GPU alignment time is linear to the sample’s
sequencing depth
Further comparison of the CPU and GPU Alignment + Mark Duplicates speed
shows increase was highly correlated to the number of GPUs dedicated to the job. Tests
were run with 2, 4, 8 GPUs dedicated to the alignment job showed an 8x, 16x, 28x speed
increase in alignment respectively (Figure 5). Showing that the GPU architecture does
not suffer from a diminishing return when increasing allocated processing units.

Figure 5: Fold speed increase of 2, 4, 8 GPUs dedicated to alignment of compared to standard
CPU alignment of two separate WGS samples.
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Turnaround Time Comparison: GPU vs CPU Pipeline
To assess full pipeline turnaround time, all 3 pipelines were run on WGS-HC and
WGS-NC samples. The TAT is compared below to show TAT from job submission
through completion for (Figure 6).

Figure 6: Comparison of TAT of GPU, CPU and hybrid pipeline, for NGS-HC and NGS-NC
samples

The GPU pipeline speeds up the fastq to VCF TAT by about 25x when compared
to the CPU pipeline. The hybrid pipeline shows roughly a 5x increase in TAT.
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Turnaround Time Comparison: Hybrid Pipeline vs CPU Pipeline
A hybrid pipeline was created by combining the Clinical CPU pipeline and
Parabricks offloads alignment, mark duplicates, and bam sorting, 3 of the longest tasks
in the Clinical CPU Pipeline. The two pipelines were run on the WGS-NC and WGS-HC
samples. A comparison was performed of the critical path steps – or the steps that are
dependent on a prior step before they can start (Figure 7).

Figure 7: Compute hours of the longest critical steps between CPU and Hybrid pipelines,
showing TAT of each step in the pipeline’s critical step for the WGS-HC and WGS-NC
samples.

WGS-NC CPU

WGS-NC Hybrid

WGS-HC CPU

WGS-HC Hybrid
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For the CPU pipeline, the alignment and mark duplicates took more than 75% of
the compute time required to complete the critical steps of the pipeline. During this
time, the resources dedicated to those tasks are both unable to be used by other tasks,
and other essential processes in the pipeline cannot proceed because they are
dependent on the aligned, sorted bam file. In the Hybrid pipeline, the alignment and
duplicates complete 25-27 fold faster, allowing for all of the downstream tasks
dependent on the completion of alignment and mark duplicate steps to complete to
start hours sooner. The hybrid pipeline completed overall 5 times faster than the CPU
pipeline did alone.
Pipeline Variant Calling Efficacy
NA12878, the NIST reference sample, was run from fastq on the clinically
validated CPU pipeline, GPU Rapid pipeline and the Hybrid pipeline. The resulting
variant call files were bed intersected using Bedtools with the NIST published high
confidence (HC) regions bed file, where many sequencing technologies were employed
to create a high confidence consensus VCF file for SNPs and small INDELs (Zook J. M.,
2019) (Quinlan, 2010). The high confidence region consists of 2,575,632,881 bases.
Variants within each pipeline’s ‘high confidence’ VCF file was compared to the published
high confidence variant call set using VCFTools’ VCF-compare function (Danecek, 2011).
Variant calls from the 3 pipelines were filtered using BCFtools to only include variants
greater than 8x depth and QUAL scores greater than 20, no other filters were used in
order to compare all three pipelines on a level playing field (Li, 2011) (Table 3).
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Table 3: Variant comparison between NIST NA12878 High Confidence variants and
assessed pipeline VCF outputs in the same regions.
Pipeline VCF file
Clinical CPU pipeline
Hybrid (GPU align
only)
Rapid (GPU)

True
Positives

False
Positives

False
Negatives

True
Negatives

3,577,524

66,604

119,070

2,571,869,683

3,577,532

67,597

118,950

2,571,868,802

3,675,949

67,419

86,782

2,571,802,731

Variant calling comparisons from all three pipelines to the NIST HC call set
showed 95.25% variant concordance for the Clinical CPU pipeline & Hybrid pipelines,
and 97.88% concordance for the GPU pipeline (Table 4). The hybrid pipeline and CPU
pipeline only had 8 different variants calls from one another, all at sites with less than
eight total reads. While the Rapid GPU pipeline had 98,417 and 98,425 more calls
matching the NIST High confidence variant call set, than the Clinical CPU and Hybrid CPU
pipeline, respectively. Performance metrics were calculated for the three pipelines to
show the overall efficacy of variant calling between the three pipelines (Table 4).

Table 4: Performance metrics showing the sensitivity, specificity, positive predictive
values and negative predictive values of all three pipelines as compared to the NIST High
Confidence Variant set.

Pipeline
Clinical CPU pipeline
Hybrid (GPU align
only)
Rapid (GPU)

Sensitivity Specificity

Positive
Negative
Predictive Value Predictive Value

0.96779

0.99997

0.98172

0.99995

0.96782

0.99997

0.98146

0.99995

0.97694

0.99997

0.98199

0.99997

22

All three pipelines return similar performance results, however, the GPU based
Rapid pipeline displayed a slightly higher sensitivity. All three pipelines show high
quality sensitivity and positive predictive value and superb specificity and negative
predictive value (Table 4).
An analysis of the discordant variants was performed to understand the
differences between each pipeline output. VCF output differences between the GPU
pipeline and the Hybrid pipeline were largely due to differences in their handling of
multiple nucleotide polymorphism calling (MNPs) (Figure 8). Functionally, the protein
product of the calls between all 4 files shown in figure 8 remain the same as the variants
are call as in-phase, meaning they occur on the same strand of DNA. The difference is in
the results format of the MNPs vs the SNPs is the format of the quality metrics produce
by the variant caller. SNPs each receive their own quality assessment, while MNPs have
their quality data merged for the combined variant.

Figure 8: IGV Screenshot showing comparisons of NIST High Confidence Callset, VCF, GPU VCF, CPU VCF and Hybrid VCF files
(top to bottom), showing the same nucleotide changes between sites, but with the Clinical and Hybrid pipelines joining the
calls as a multiple nucleotide polymorphism, while the NIST and GPU pipelines call two separate MNPs.

DISCUSSION
Turnaround Time and Efficiency
Implementation of Parabricks GPU enabled bioinformatic tools displays a clear
advantage for process turnaround time. Two samples were selected for test runs: an
average depth genome WGS-NC (~55x), and WGS-HC (~150x). The genomes were run
on the Parabricks germline pipeline with 8 GPUs dedicated and CPU pipeline with 8
CPUs dedicated to assessing the turnaround time of the two alignments. The results
were then used to create estimations below were made for a standard 35x coverage
genome. 35x TAT assumptions were made under the assumptions that CPU and GPU
compute hours are linear to the sequencing depth, and compute hours in Table 5 are
available.

Table 5: Estimated CPU/GPU core hours available per year in the cluster described in
this experiment.
CPU core hours avail per year

2,978,400

GPU core hours avail per year

70,080

This analysis estimates that a 35x coverage genome sample will require a total of
836 CPU hours per genome. Using the estimations in table 5, this means the CPU cluster
described in this document can run roughly 3,562 genomes annually (Table 6).

25

Table 6: Estimated number of genomes able to be processed annually by the CPU
pipeline alone on the cluster described in this document.
Assay
WGS

CPU Hour estimation
(hours/sample)
836

Maximum
throughput per year
3,562

Based on the results of this experiment implementation of the hybrid pipeline,
hence offloading the alignment to the GPU, would offload roughly 101.8 CPU hours per
whole genome pipeline run. Using the core hour estimations described in Table 5, we
can estimate how many more genomes can be run annually before saturating the
system (Table 7). Simply adding Parabricks GPU alignment and Mark Duplicates into
CPU pipeline, the cluster described in this document can process 456 (11.3%) more
genomes through the pipeline, with faster turnaround time.

Table 7: An estimate of the number of 35x depth genomes that could be run annually on
the CPU and GPU cluster described within this document via the Hybrid pipeline.

CPU Hour
estimation
(Alignment
excluded)

GPU Hour
estimation
(Alignment +
Mark
duplicates
only)

Maximum CPU
processing
(all pipeline steps
excluding alignment,
mark duplicates, BQSR)

727.9

4.36

4,092

Maximum
GPU
processing
(alignment +
Mark
duplicates
only)
4,018

Maximum
throughput
per year

4,018

Running the Parabricks Rapid pipeline alone, assuming 35x coverage and 100%
up time, a single DGX GPU system could process 2,037 genomes in a year (Table 8).
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Table 8: An estimate of the number of 35x whole genome pipeline runs that could be
run annually on the CPU and GPU cluster described within this document via the
Parabricks alone.
GPU Core Hour
estimation (hours)
17.20

Maximum WGS
throughput per year
2,037

It is worth noting that the CPU and hybrid pipelines have more quality control
steps built in than the GPU pipeline. Steps including GATK DepthOfCoverage,
calculation of coverage for all gene regions and variant quality checks are extremely
important steps for quality control and quality assurance in any clinical workflow. These
steps ensure that all regions of the genome are accurately represented within the
sample, helping analysts ensure that lack of variation is not confounded with lack of
sequencing data. The power of the hybrid pipeline is the shortened of alignment, the
longest step in the pipeline, combined with the added QC performed by the pipeline.
Shortening required alignment time allows for all other dependent tasks start
processing sooner, allowing for more efficient distribution of downstream jobs
throughout the rest of the pipeline. In contrast, the clinical CPU workflow has a major
bottleneck at the alignment step. While the CPU alignment is occurring, all other
downstream jobs are waiting for alignment to complete, leading to an imbalance of CPU
demand towards the end of the pipeline.
Given the speed of the GPU pipeline, another potential method for reducing
overall WGS TAT is using Parabricks for both alignment and variant calling, then using
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slower CPU quality assessments while the clinical variant assessment of the resulting
VCF begins. The prospect of this is extremely attractive, as it would allow a clinical to go
from DNA to analysis within two days. Allowing for one day on the sequencer, 2-5 hours
for Parabricks to generate a VCF, and finally uploading to analysis software. Meanwhile,
QC steps performed on the BAM and VCF can occur simultaneously. If any quality issues
such as low coverage or low quality are found, clinical variant analysis can be halted,
and sequencing can be repeated to improve quality.
Variant Calling Efficacy
A bioinformatic pipeline is only as useful as it is accurate. To ensure the pipelines
tested herein produce accurate variant calls, whole genome sequencing of the NIST
Gold Standard reference sample NA12878, was run on each pipeline (Zook J. M., 2019).
The results for all pipelines showed a high degree of efficacy for use in a clinical setting.
In comparison with the gold standard within the high confidence regions, the Clinically
validated CPU pipeline showed the worst sensitivity and positive predictive value (PPV),
at 96.78% and 98.17%, respectively. The Hybrid pipeline showed slightly better
sensitivity and PPV, at 96.78 and 98.15%, respectively. The rapid pipeline showed by far
the most robust sensitivity and PPV, at 97.69% and 98.19%, respectively.
While all three pipelines show impressive results, it is notable that raw variant
concordance can be slightly misleading. As mentioned earlier, the Rapid pipeline has
very little built in QC. Figure 9 shows a single variant within a homopolymer repeat of
the NIST High-Confidence Variant call set. The NIST high confidence variant set only
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reports a single mutation within the region, at GRCh37 locus chr15:20,024,978. With
the exception of the Rapid pipeline calling two separate A > T mutations, rather than a
multiple nucleotide polymorphism (MNP) of AAA>TAT, all three pipelines report the
same variants within this region. Notably in Figure 9, the hybrid and CPU pipelines show
called variants with the exception the variant at site chr15:20,024,978 being ‘grayed
out’, due to low quality flags being triggered in the GATK Variant Filtration quality
control step (GATK (Best Practices), 2020). These low-quality variants are reported in
the VCF and are discordant from the NIST HC variants, the low-quality flag in the ‘FILTER’
column allows for an analyst or automated filter set to easily pass over these variants.
Despite having the highest raw sensitivity, specificity, PPV, and NPV, the Rapid GPU
pipeline has no such variant filtering step, meaning any doubtful variants must be
scrutinized more by genomic analyst. Given the superior speed of the GPU pipeline, it is
more than reasonable to add an additional variant QC step to the end of the pipeline to
reduce or flag low confidence variant calls in the resulting VCF.

Figure 9: An IGV screenshot of a low complexity genomic region showing the High Confidence callset and all three pipeline
outputs. The clinical CPU and Hybrid pipelines show grayed out, ‘filtered’ variants that are called, but flagged as
untrustworthy.

Clinical Efficacy
All three pipelines display the sensitivity, specificity, PPV and NPV that is
required of a clinical pipeline. The Rapid GPU pipeline shows great promise for clinical
work, showing the ability to decrease bioinformatic workflow turnaround times. This is
especially useful in cases of neo-natal crises, or other emergent situations where an
early detection/diagnosis of diseases could prevent irreversible damage (Kingsmore,
2012). In these cases, whole genome sequencing has become a first line of defense for
clinicians unable to diagnose disease by conventional diagnostic methods (Bodian,
2014). The largest draw back for these cases is the turnaround time for genome
sequencing and reporting – which can take upwards of a month. Implementing the
Rapid GPU pipeline in these scenarios offers a massive speed up and could save lives in
the process.
One of the notable drawbacks of the Rapid GPU pipeline as outlined in this study
is the lack of built in quality control and quality assurance steps. While this is true, the
data outputs from the Rapid pipeline are in standard bioinformatic formats can easily be
picked up by CPU based quality control methods. CPU quality control steps can be
applied to Parabricks GPU outputs, as demonstrated within the hybrid pipeline. In the
cases of neonatal crisis, genomic analysis of variants could even begin immediately upon
the completion of the Rapid GPU pipeline. Slower, CPU quality control steps could be
performed in parallel to the initial clinical analysis. Once quality control steps complete,
the results can be assessed accordingly. Combinations of the CPU and GPU methods
could cut hours and even days from results generation for genomic workflows.

CONCLUSIONS
GPU based workflows are rapidly transforming the landscape of many HPC
processes, especially in fields dependent on getting results quickly. Genomics and
bioinformatics present a perfect application for using GPUs to speed up computational
workflows due to their ‘ridiculously parallel’ nature. This study shows that Parabricks
and its suite of genomics tools provide massive speed boost to current state of the art
clinical workflows, cutting the time from job submission to results by four to five-fold.
Some additional work needs to be done to Parabricks add quality control steps into the
germline workflow. The ‘Hybrid Pipeline’ discussed within this study presents a
reasonable method to both reduce turnaround time and makes use of quality control
features present within the CPU based pipeline by adding CPU tools such as GATK’s
Variant filtration or VQSR (GATK (Best Practices), 2020).
Parabricks’ speed and throughput increase for WGS processing also may provide
a roundabout solution to the massive data volume produced by WGS pipelines. As
Parabricks drastically reduces the compute time for creating and recreating genomic
data, output data could be deleted after analysis and only the smaller, raw sequencing
data files kept long term. This method would result in a drastic reduction of overall
clinical data burden on clinical labs. By only keeping raw data and rapidly recreating
results on request, clinical labs may be able to lower prices on WGS clinical tests and
provide greater accessibility of WGS testing to patients.

32

In the context of clinical care, the speed of Parabricks GPU bioinformatic tools
has been shown to reduce overall WGS bioinformatic pipeline processing time by days.
Coupled with innovative analysis methods, such as starting variant analysis as soon as
variant call files are ready, the processes Parabricks facilitates could cut up to a week
from overall TAT. While seemingly minimal, the reduced turnaround time can save lives
by diagnosing diseases and starting treatments or clinical trials sooner or assist clinicians
and families in the decision to start palliative care sooner. The reduction in TAT can
reduce the overall cost of treatment for patients by providing them a personalized care
plan which can shorten inpatient hospital stays. Finally, quicker results can reduce
stress for families and clinicians alike by providing the most comprehensive test possible
in a shorter time frame.
Parabricks exhibits clinical efficacy showing high sensitivity, specificity, PPV and
NPV that is ready for use right out of the box. While minimal quality control is included
in its standard workflow, the Parabricks suite of tools provides configurable modules
that can be included in combined CPU and GPU pipelines. Used wisely, Parabricks and
GPUs can bring whole genome sequencing closer to a routine clinical test, rather than a
last-ditch effort.
Future Studies
Future work surrounding the use of Parabricks and GPUs should be centered
around applying additional quality control mechanisms to Parabricks Rapid GPU
pipeline. One such direction would be the application of variant filter fields such as
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GATK’s VQSR, or GATK’s Filter variants (GATK (Best Practices), 2020). Resulting Rapid
GPU filtered VCFs then can be more meaningfully compared to one another compared
against the filtered VCFs from the Clinical CPU pipeline. The resulting comparison would
give additional weight to the clinical efficacy of the GPU pipeline. Another useful quality
control feature that could be added to the GPU pipeline are DepthOfCoverage and Bam
Statistics by BamTools (Barnett, 2011). These additional comparisons and quality
control steps would add the necessary quality control to go live with WGS bioinformatic
analysis by Parabricks GPU pipelines.
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